2008 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
April 02, 2008
InNexus Biotechnology to Present Data at AACR -- New DXL625 (CD20) Data Demonstrates Superiority Versus Competing CD20 Antibodies --
BRITISH COLUMBIA, Canada-02 April 2008-InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™),announced that they will be presenting new in vivo proof of principle data at the American Association for Cancer Research in San Diego, California on April 15, 2008.
Dr. Thomas Kindt, InNexus Biotechnology’s Chief Scientific Officer stated, “We will be presenting a comprehensive set of data showcasing the kinetic advantages seen with DXL™ enhanced anti-CD20 antibodies, as well as a novel B-cell depletion model. Our data shows that DXL625 resulted in a significant reduction in B-lymphocytes in rabbits while a competing commercialized anti-CD20 antibody was shown to result in no such reduction.”
“This newly acquired data demonstrates the in vivo superiority of DXL625 as compared to competing commercialized CD20 antibodies, without an increase in toxicity or immunogenicity,” said Jeff Morhet, Chairman and CEO. “This paves the way toward the next steps in our development of DXL625, which includes a kickoff of primate studies and ultimately, an IND submission to the FDA.”
Following InNexus’ presentation at AACR on April 15th, the data presented will be available via the InNexus website at http://www.ixsbio.com.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet, Chairman & Chief Executive Officer
Dr. Thomas Kindt, Chief Scientific Officer
InNexus Biotechnology Inc.
480-862-7500
www.ixsbio.com
